Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
Primary central nervous system lymphoma (PCNSL) is a rare, extranodal form of non-Hodgkin lymphoma that most commonly presents with neurologic changes. Comprehensive workup to diagnose PCNSL and rule out nodal non-Hodgkin lymphoma is critical to the development of an appropriate plan for therapy. Past PCNSL treatments have included whole-brain radiation or steroids, but high-dose methotrexate (MTX) has emerged as initial therapy. Although high-dose MTX is well tolerated, special considerations must be taken to administer the drug safely. Specific interventions include aggressive IV hydration with sodium bicarbonate fluids, monitoring blood chemistries, and the administration of leucovorin rescue. Nurses should evaluate and monitor patients closely during treatment to ensure safety and decrease drug toxicity.
The Medical Center Clinic, The West Penn Allegheny Oncology Network, Kittanning, PA, USA. ewarnick@wpaon.org
Elizabeth
E
Warnick
Danielle
D
Auger
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy*; D004268:DNA-Binding Proteins / Q000235:genetics; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000235:genetics; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics; D008727:Methotrexate / Q000627:therapeutic use*; D051560:Proto-Oncogene Proteins c-bcl-6
D000964:Antimetabolites, Antineoplastic; C084103:BCL6 protein, human; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6; D008727:Methotrexate